capivasertib Truqap
Selected indexed studies
- Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. (N Engl J Med, 2023) [PMID:37256976]
- Capivasertib: First Approval. (Drugs, 2024) [PMID:38388873]
- Capivasertib (Truqap) for breast cancer. (Med Lett Drugs Ther, 2024) [PMID:38412269]
_Worker-drafted node — pending editorial review._
Connections
capivasertib Truqap is a side effect of
Sources
- Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: CAPItello-281 phase III study. (2026) pubmed
- Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial. (2024) pubmed
- Capivasertib and fulvestrant for patients with hormone receptor-positive advanced breast cancer: characterization, time course, and management of frequent adverse events from the phase III CAPItello-291 study. (2024) pubmed
- Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer. (2023) pubmed
- Capivasertib: First Approval. (2024) pubmed
- Capivasertib (Truqap) for breast cancer. (2024) pubmed
- PMID:39466922 (2024) pubmed
- Capivasertib: A Novel AKT Inhibitor Approved for Hormone-Receptor-Positive, HER-2-Negative Metastatic Breast Cancer. (2024) pubmed
- Capivasertib. (2006) pubmed
- Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. (2020) pubmed